Canadian Guidelines on Pharmacotherapy for Disruptive and Aggressive Behaviour in Children and Adolescents with Attention-Deficit Hyperactivity Disorder,Oppositional Defiant Disorder,or Conduct Disorder
Free accessResearch articleFirst published online February, 2015
Canadian Guidelines on Pharmacotherapy for Disruptive and Aggressive Behaviour in Children and Adolescents with Attention-Deficit Hyperactivity Disorder,Oppositional Defiant Disorder,or Conduct Disorder
To develop evidence-based guidelines on pharmacotherapy for severe disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), or conduct disorder (CD). The guidelines assume that psychosocial interventions have been pursued but did not achieve sufficient improvement.
Method:
A multidisciplinary consensus group used the Grading of Recommendations Assessment, Development and Evaluation approach for rating evidence quality and for grading recommendations. We conducted a systematic review of medications studied in placebo-controlled trials for treating disruptive and aggressive behaviour in children and adolescents with ADHD, ODD, or CD. We followed consensus procedures to make 1 of 4 recommendations for each medication: strong, in favour (↑↑); conditional, in favour (↑?); conditional, against (↓?); and strong, against (↓↓).
Results:
For children and adolescents with disruptive or aggressive behaviour associated with ADHD, psychostimulants received a strong recommendation in favour of use, while atomoxetine and alpha-2 agonists received a conditional recommendation in favour of use. If these patients do poorly with ADHD medications, the medication with the most evidence is risperidone. Risperidone also has the most evidence for treating disruptive or aggressive behaviour in the absence of ADHD. However, given risperidone's major adverse effects, it received only a conditional recommendation in favour of use. We recommended against using quetiapine, haloperidol, lithium, or carbamazepine because of the poor quality of evidence and their major adverse effects.
Conclusion:
When severe disruptive or aggressive behaviour occurs with ADHD, medications for ADHD should be used first. Other medications have major adverse effects and, with the exception of risperidone, very limited evidence to support their use.
StringarisAGoodmanR.Longitudinal outcome of youth oppositionality: Irritable, headstrong, and hurtful behaviors have distinctive predictions. J Am Acad Child Adolesc Psychiatry. 2009;48(4):404–412.
2.
ColmanIMurrayJAbbottRA, Outcomes of conduct problems in adolescence: 40 year follow-up of national cohort. BMJ. 2009;338:a2981.
3.
CleverleyKSzatmariPVaillancourtT, Developmental trajectories of physical and indirect aggression from late childhood to adolescence: Sex differences and outcomes in emerging adulthood. J Am Acad Child Adolesc Psychiatry. 2012;51(10):1037–1051.
4.
GrolRBuchanH.Clinical guidelines: What can we do to increase their use?Med J Aust. 2006;185(6):301–302.
5.
GrahamIDLoganJHarrisonMB, Lost in knowledge translation: Time for a map?J Contin Educ Health Prof. 2006;26(1):13–24.
6.
KnappPChaitAPappadopulosE, Treatment of maladaptive aggression in youth: CERT guidelines I. Engagement, assessment, and management. Pediatrics. 2012;129(6):e1562–e1576.
7.
Scotto RosatoNCorrellCUPappadopulosE, Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. Pediatrics. 2012;129(6):e1577–e1586.
8.
PringsheimTLamDPattenSB. The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005–2009. J Child Adolesc Psychopharmacol. 2011;21(6):537–543.
9.
OlfsonMBlancoCLiuSM, National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69(12):1247–1256.
10.
PringsheimTGormanD.Second-generation antipsychotics for the treatment of disruptive behaviour disorders in children: A systematic review. Can J Psychiatry. 2012;57(12):722–727.
11.
PringsheimTLamDChingH, Metabolic and neurological complications of second-generation antipsychotic use in children: A systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011;34(8):651–668.
12.
GuyattGOxmanADAklEA, GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–394.
13.
GuyattGVistGFalck-YtterY, An emerging consensus on grading recommendations?ACP J Club. 2006;144(1):A8–A9.
14.
PringsheimTHirschLGardnerD, The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: A systematic review and meta-analysis. Part 1: Psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry. 2015;60(2):42–51.
15.
PringsheimTHirschLGardnerD, The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: A systematic review and meta-analysis. Part 2: Antipsychotics and traditional mood stabilizers. Can J Psychiatry. 2015;60(2):52–61.
16.
SnyderRTurgayAAmanM, Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41(9):1026–1036.
17.
AmanMGDe SmedtGDerivanA, Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159(8):1337–1346.
18.
Van BellinghenMDe TrochC.Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol. 2001;11(1):5–13.
19.
BuitelaarJKvan der GaagRJCohen-KettenisP, A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62(4):239–248.
20.
FindlingRLMcNamaraNKBranickyLA, A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(4):509–516.
21.
ArmenterosJLLewisJEDavalosM.Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: A placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007;46(5):558–565.
22.
AmanMGBuksteinOGGadowKD, What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?J Am Acad Child Adolesc Psychiatry. 2014;53(1):47–60.e1.
23.
BrozekJLAklEACompalatiE, Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy. 2011;66(5):588–595.
24.
SurveyMonkey. SurveyMonkey [Internet survey software]. Palo Alto (CA): SurveyMonkey; 1990–2014 [cited 2014 Jan 17]. Available from: www.surveymonkey.com. Canadian office: Ottawa, ON.
25.
AndrewsJGuyattGOxmanAD, GRADE guidelines: 14. Going from evidence to recommendations: The significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719–725.
26.
ConnorDFGlattSJLopezID, Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41(3):253–261.
27.
ArnoldLE. Methylphenidate vs amphetamine: Comparative review. J Atten Disord. 2000;3:200–211.
28.
TreuerTGauSSMendezL, A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. J Child Adolesc Psychopharmacol. 2013;23(3):179–193.
29.
BangsMETauscher-WisniewskiSPolzerJ, Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry. 2008;47(2):209–218.
30.
SchwartzSCorrellCU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: Results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53(2):174–187.
31.
ChenQSjolanderARunesonB, Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: Register based study. BMJ. 2014;348:g3769.
32.
BiedermanJMelmedRDPatelA, A randomized, doubleblind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73–e84.
33.
SalleeFRMcGoughJWigalT, Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155–165.
GeyskesGGBoerPDorhout MeesEJ. Clonidine withdrawal. Mechanism and frequency of rebound hypertension. Br J Clin Pharmacol. 1979;7(1):55–62.
36.
GadowKDArnoldLEMolinaBS, Risperidone added to parent training and stimulant medication: Effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. J Am Acad Child Adolesc Psychiatry. 2014;53(9):948–959.e1.
37.
ReyesMBuitelaarJTorenP, A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry. 2006;163(3):402–410.
38.
CuevaJEOverallJESmallAM, Carbamazepine in aggressive children with conduct disorder: A double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 1996;35(4):480–490.
39.
CampbellMSmallAMGreenWH, Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry. 1984;41(7):650–656.
40.
BladerJCSchoolerNRJensenPS, Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry. 2009;166(12):1392–1401.
41.
DonovanSJStewartJWNunesEV, Divalproex treatment for youth with explosive temper and mood lability: A doubleblind, placebo-controlled crossover design. Am J Psychiatry. 2000;157(5):818–820.
42.
MaloneRPDelaneyMALuebbertJF, A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry. 2000;57(7):649–654.
43.
RifkinAKarajgiBDickerR, Lithium treatment of conduct disorders in adolescents. Am J Psychiatry. 1997;154(4):554–555.
44.
CampbellMAdamsPBSmallAM, Lithium in hospitalized aggressive children with conduct disorder: A double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 1995;34(4):445–453.
45.
HeresSDavisJMainoK, Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163(2):185–194.
46.
SpielmansGIParryPI. From evidence-based medicine to marketing-based medicine: Evidence from internal industry documents. J Bioeth Inq. 2010;7(1):13–29.
47.
SeixasMWeissMMullerU.Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol. 2012;26(6):753–765.
48.
FaraoneSV. Understanding the effect size of ADHD medications: Implications for clinical care. Medscape Psychiatr Ment Health. 2003;8(2).
49.
HirotaTSchwartzSCorrellCU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: A systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry. 2014;53(2):153–173.
50.
HaasMUnisASArmenterosJ, A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19(6):611–621.
51.
HaasMDelbelloMPPandinaG, Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: A randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009;11(7):687–700.
52.
AmanMGMarksRETurbottSH, Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. J Am Acad Child Adolesc Psychiatry. 1991;30(2):246–256.
53.
PringsheimTPanagiotopoulosCDavidsonJ, Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health. 2011;16(9):581–589.
54.
HoJPanagiotopoulosCMcCrindleB, Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. Paediatr Child Health. 2011;16(9):575–580.
55.
PringsheimTDojaABelangerS, Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatr Child Health. 2011;16(9):590–598.
56.
ChongLYNasserMGlasziouP.What should we call weak recommendations?Newsl Int Soc Evid Based Health Care. 2011;2:6–7.
57.
Eli Lilly Canada Inc. Strattera (atomoxetine capsules) [product monograph]. Toronto (ON): Eli Lilly Canada Inc; 2014 Sep 4.
AztraZeneca Canada Inc. Seroquel quetiapine fumarate immediate-release tablets [product monograph]. Mississauga (ON): AztraZeneca Canada Inc; 2013 Dec 20.
61.
Abbott Canada. Epival (divalproex sodium enteric-coated tablets) [product monograph]. Saint-Laurent (QC): Abbott Laboratories, Limited; 2013 Nov 8 [date of revision].
62.
ERFA Canada 2012 Inc. Lithane lithium carbonate capsules [prescribing information; product monograph]. Montreal (QC): ERFA Canada Inc;20122013 Jul 4.
63.
VitielloB.Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am. 2008;17(2):459–474, xi.
64.
MosholderADGelperinKHammadTA, Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics. 2009;123(2):611–616.
65.
US Food and Drug Administration (FDA). Methylphenidate ADHD medications: Drug safety communication—risk of long-lasting erections. Silver Spring (MD): US FDA; 2013 Dec 17.
66.
BélangerSAWarrenAEHamiltonRM, Cardiac risk assessment before the use of stimulant medications in children and youth. Paediatr Child Health. 2009;14(9):579–592.
67.
StiefelGBesagFM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf. 2010;33(10):821–842.
68.
BangsMEJinLZhangS, Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. 2008;31(4):345–354.
69.
BiedermanJMelmedRDPatelA, Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008;13(12):1047–1055.
70.
SalleeFRLyneAWigalT, Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(3):215–226.
71.
CantwellDPSwansonJConnorDF. Case study: Adverse response to clonidine. J Am Acad Child Adolesc Psychiatry. 1997;36(4):539–544.
72.
Treatment of ADHD in children with tics: A randomized controlled trial. Neurology. 2002;58(4):527–536.
73.
LabellarteMJCrossonJERiddleMA. The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2003;42(6):642–650.
74.
CorrellCUPenznerJBParikhUH, Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2006;15(1):177–206.
75.
De HertMSchreursVSweersK, Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophr Res. 2008;101(1–3):295–303.
76.
MoisanJTurgeonMDesjardinsO, Comparative safety of antipsychotics: Another look at the risk of diabetes. Can J Psychiatry. 2013;58(4):218–224.
77.
NanauRMNeumanMG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013;46(15):1323–1338.
78.
VerrottiAScaparrottaAGrossoS, Anticonvulsant drugs and hematological disease. Neurol Sci. 2014;35(7):983–993.
79.
JoffeHCohenLSSuppesT, Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry. 2006;59(11):1078–1086.
80.
PettySJO'BrienTJWarkJD. Anti-epileptic medication and bone health. Osteoporos Int. 2007;18(2):129–142.
81.
KoenigSABuesingDLonginE, Valproic acid-induced hepatopathy: Nine new fatalities in Germany from 1994 to 2003. Epilepsia. 2006;47(12):2027–2031.
82.
GerstnerTBusingDBellN, Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol. 2007;42(1):39–48.
GerstnerTBuesingDLonginE, Valproic acid induced encephalopathy—19 new cases in Germany from 1994 to 2003—a side effect associated to VPA-therapy not only in young children. Seizure. 2006;15(6):443–448.
LeviNBastuji-GarinSMockenhauptM, Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: A pooled analysis. Pediatrics. 2009;123(2):e297–e304.
87.
PatornoEBohnRLWahlPM, Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA. 2010;303(14):1401–1409.
McKnightRFAdidaMBudgeK, Lithium toxicity profile: A systematic review and meta-analysis. Lancet. 2012;379(9817):721–728.
90.
DolsASienaertPvan GervenH, The prevalence and management of side effects of lithium and anticonvulsants as mood stabilizers in bipolar disorder from a clinical perspective: A review. Int Clin Psychopharmacol. 2013;28(6):287–296.
91.
PellockJM. Carbamazepine side effects in children and adults. Epilepsia. 1987;28(Suppl 3):S64–S70.
92.
DongXLeppikIEWhiteJ, Hyponatremia from oxcarbazepine and carbamazepine. Neurology. 2005;65(12):1976–1978.
93.
SalimipourHKazerooniSSeyedabadiM, Antiepileptic treatment is associated with bone loss: Difference in drug type and region of interest. J Nucl Med Technol. 2013;41(3):208–211.
94.
DurelliLMutaniRSechiGP, Cardiac side effects of phenytoin and carbamazepine. A dose-related phenomenon?Arch Neurol. 1985;42(11):1067–1068.
95.
Bou KhalilRRichaS.Thyroid adverse effects of psychotropic drugs: A review. Clin Neuropharmacol. 2011;34(6):248–255.
96.
European Commission, Enterprise and Industry Directorate-General. A guideline on summary of product characteristics (SmPC). Revision 2 [Internet].Brussels (BE): European Commission; 2009 Sep [cited 2014 Jun 10]. Available from: http://ec.europa.eu/health/fles/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf.
97.
Micromedex Solutions. Micromedex 2.0 [Internet].Ann Arbor (MI): Truven Health Analytics; c1974–2014 [cited 2014 Jun 10]. Available from: http://www.micromedexsolutions.com.
98.
SwansonJMElliottGRGreenhillLL, Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1015–1027.
99.
CooperWOHabelLASoxCM, ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896–1904.
100.
WintersteinAGGerhardTKubilisP, Cardiovascular safety of central nervous system stimulants in children and adolescents: Population based cohort study. BMJ. 2012;345:e4627.
101.
OlfsonMHuangCGerhardT, Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(2):147–156.
102.
SchellemanHBilkerWBStromBL, Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127(6):1102–1110.
